Tyrosine Hydroxylase-Deficient Dopa-Responsive Dystonia (TH-deficient DRD)

Tyrosine hydroxylase–deficient dopa-responsive dystonia is a rare, inherited movement disorder. It happens because the TH gene does not work properly. The TH gene makes the tyrosine hydroxylase enzyme. This enzyme turns the amino acid tyrosine into L-DOPA, which the brain uses to make dopamine. When TH does not work, the brain cannot make enough dopamine. Low dopamine causes muscle tightness, abnormal postures, slow movement, and walking problems. Many children show symptoms in early life. A special feature is that symptoms often get much better with low-dose levodopa, a medicine that replaces missing dopamine. Because of this strong medicine response, doctors call it “dopa-responsive dystonia.” MedlinePlus+2NCBI+2

Tyrosine hydroxylase–deficient dopa-responsive dystonia (TH-DRD) is a rare, inherited brain chemistry problem. The body cannot make enough dopamine because the enzyme tyrosine hydroxylase (TH) is not working well. TH is the “first step” enzyme that turns the amino acid tyrosine into L-DOPA, which then becomes dopamine. Low dopamine leads to dystonia (involuntary muscle pulling), stiffness, slow movement, and sometimes tremor. Symptoms often improve after taking levodopa (a form of dopamine replacement), which is why it is called “dopa-responsive.” This condition is autosomal recessive and caused by changes (variants) in the TH gene. CSF studies usually show low dopamine breakdown products (like HVA) with normal or near-normal serotonin metabolite (5-HIAA) in many cases. Pedneur+3PMC+3NCBI+3

Other names

You may see several names for the same condition. These names reflect the gene, the enzyme, or how the illness looks in patients:

• Tyrosine hydroxylase deficiency (TH deficiency; THD)

• TH-deficient dopa-responsive dystonia

• Autosomal recessive dopa-responsive dystonia (DYT5b)

• Autosomal recessive Segawa syndrome

• Dopa-responsive infantile parkinsonism (for severe early forms)
  All of these point to the same biological problem: a shortage of brain dopamine due to TH gene variants. Orpha.net+2Orpha.net+2

Types

Doctors often describe three clinical types, based on how severe symptoms are and how well levodopa helps:

1. Mild (classic DRD type). Childhood-onset dystonia, often with leg stiffness and an “in-turned” foot. Symptoms can fluctuate during the day and usually respond very well to low-dose levodopa. MedlinePlus+1

2. Moderate (intermediate) type. Dystonia plus some features of parkinsonism (slowness, rigidity), sometimes with developmental or speech delay. Levodopa helps, but not always completely. Wiley Online Library

3. Severe (infantile parkinsonism/encephalopathy) type. Early-infant symptoms such as global hypotonia, poor feeding, eye movement crises (oculogyric crises), autonomic problems, and profound motor delay. Levodopa may help only partly. OUP Academic+1

Causes

This disorder is genetic. The root cause in every patient is two disease-causing variants (biallelic) in the TH gene. Below are 20 concrete causes and contributors doctors recognize. Items 1–8 are direct genetic causes; items 9–20 are contributors/modifiers that can shape when and how strongly symptoms appear.

1. Biallelic TH gene variants. You inherit one faulty copy from each parent. This blocks the TH enzyme and lowers dopamine production. MedlinePlus+1

2. Missense variants. A single amino-acid change reduces enzyme activity and lowers dopamine output. NCBI

3. Nonsense/frameshift variants. These create truncated enzyme protein or none at all, leading to severe enzyme loss. NCBI

4. Splice-site variants. These disrupt proper RNA splicing so the enzyme is not built correctly. NCBI

5. Promoter or regulatory variants. These lower TH gene expression so less enzyme is made. OUP Academic

6. Large deletions/duplications within TH. Missing or extra DNA segments can remove key domains of the enzyme. providers.genedx.com

7. Compound heterozygosity. Two different harmful variants (one on each copy) are enough to cause disease. OUP Academic

8. Consanguinity (shared ancestry). Increases the chance both parents carry the same variant. Wiley Online Library

9. Natural enzyme cofactor limits. TH needs the cofactor BH₄; when BH₄ availability is relatively low, dopamine synthesis can drop further (even though classic THD is not a primary BH₄ disorder). OUP Academic

10. Illness or fever. Stress and catabolic states can temporarily worsen dopamine shortage and symptoms. OUP Academic

11. Sleep loss and fatigue. These can aggravate motor symptoms and daily fluctuations. Movement Disorders

12. Physical overexertion. Fatigued muscles reveal underlying dystonia and bradykinesia more clearly. Movement Disorders

13. Psychological stress. Stress can increase muscle tone and dystonia severity. Movement Disorders

14. Certain dopamine-blocking medicines. Drugs like some antipsychotics or anti-nausea agents block dopamine receptors and can worsen symptoms. OUP Academic

15. Low iron status. Iron is a cofactor partner in catecholamine biology; low iron may subtly affect dopamine pathways. OUP Academic

16. Perinatal stress. Early life stressors can unmask severe infantile phenotypes. PubMed

17. Intercurrent infections. Temporary worsening of dystonia and autonomic signs can occur during infections. OUP Academic

18. Rapid growth periods. Higher dopamine needs during growth can expose deficits. OUP Academic

19. Poor levodopa access or adherence. Without drug replacement, symptoms persist or progress. NCBI

20. Delayed diagnosis. Later start of treatment can allow fixed contractures or scoliosis to develop. Early levodopa usually prevents this. American Academy of Neurology

Note: Items 9–20 are modifiers/triggers; the disease-causing mechanism is always reduced TH enzyme activity from TH gene variants. OUP Academic

Symptoms

Symptoms vary by child, but most relate to low dopamine affecting movement and the autonomic system.

1. Dystonia. Involuntary muscle contractions cause twisting postures or abnormal gait, often starting in a leg. National Organization for Rare Disorders

2. Diurnal fluctuation. Symptoms are milder after sleep and worsen later in the day. This day–night pattern is a classic clue. Movement Disorders

3. Bradykinesia (slowness). Movements start slowly and feel effortful. PMC

4. Rigidity. Stiff muscles, especially in arms and legs. PMC

5. Hypokinesia. Reduced movement overall; the child may look still or hesitant to move. PMC

6. Abnormal gait. In-toeing, toe-walking, or limping; running may be hard. National Organization for Rare Disorders

7. Oculogyric crises. Brief episodes where the eyes roll upward with discomfort or agitation. PMC

8. Tremor. Some children develop a fine or resting tremor. OUP Academic

9. Autonomic symptoms. Drooling (salivation), sweating, and sometimes temperature instability. PMC

10. Axial hypotonia in infants. “Floppy” trunk control and delayed head holding in severe forms. OUP Academic

11. Feeding difficulty in infants. Poor suck or swallowing in severe cases. PubMed

12. Speech delay or low voice. Dopamine scarcity can affect speech initiation and volume. OUP Academic

13. Developmental delay. Motor milestones may be late without treatment. Wiley Online Library

14. Painful muscle cramps. Due to sustained dystonic contractions. OUP Academic

15. Excellent response to levodopa. A dramatic and sustained improvement with low doses is typical in many patients and is itself a clinical “symptom signature.” NCBI

Diagnostic tests

Diagnosis combines the story (history), the exam, select manual/bedside tests, laboratory studies on neurotransmitters and genetics, and imaging mainly to rule out other problems. A careful therapeutic trial of low-dose levodopa is both practical and informative.

A) Physical examination

1. Observation of dystonia pattern. The clinician watches sitting, standing, and walking. Typical patterns include foot inversion, toe-walking, and leg-dominant dystonia. This pattern, plus worsening late in the day, points to DRD. Movement Disorders

2. Parkinsonism screen. The doctor checks for slowness, rigidity, masked facial expression, and small steps. Finding parkinsonian signs in a child suggests a dopamine shortage disorder. OUP Academic

3. Diurnal variation check. Re-examining early morning versus evening often shows clear fluctuation, a hallmark of DRD. Movement Disorders

4. Autonomic review. Excess sweating, drooling, and episodes like oculogyric crises suggest a catecholamine deficit. PMC

5. Developmental and growth assessment. In moderate-to-severe forms, tone, posture, feeding, and milestones help stage severity and guide urgency of treatment. Wiley Online Library

B) Manual/bedside functional tests

6. Gait testing (tandem and heel-toe walk). These simple walks reveal dystonic foot postures and balance problems; change across the day is informative. Movement Disorders

7. Tone and range-of-motion testing. Gentle passive movement shows “lead-pipe” rigidity or catch-like resistance from dystonia; limited range suggests long-standing spasm. OUP Academic

8. Pull test for postural stability. A quick backward tug checks balance reactions; impaired correction supports parkinsonian features. OUP Academic

9. Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS). A standardized score to rate baseline dystonia and track response to levodopa over time. Frontiers

10. Levodopa test dose (supervised). A carefully supervised low-dose levodopa with a decarboxylase inhibitor (e.g., carbidopa) can show striking improvement within days to weeks in typical DRD. This is both diagnostic and therapeutic. NCBI

C) Laboratory and pathological studies

11. Cerebrospinal fluid (CSF) neurotransmitter metabolites. In TH deficiency, HVA (homovanillic acid) and MHPG are low, reflecting low dopamine and norepinephrine; pterins are usually normal—helping distinguish TH deficiency from primary BH₄ disorders. OUP Academic

12. Genetic testing of the TH gene. Finding two pathogenic TH variants confirms the diagnosis. Panels for “dystonia/neurotransmitter disorders” or exome sequencing commonly detect these. PubMed

13. Targeted variant analysis in families. Once a family’s variants are known, relatives can be tested for carrier status or early diagnosis. MedlinePlus

14. Serum prolactin. Dopamine suppresses prolactin; with dopamine scarcity, prolactin may be elevated, which can support the picture though it is not specific. OUP Academic

15. Basic labs (to exclude mimics). Thyroid tests, copper/ceruloplasmin (for Wilson disease), and metabolic screens help rule out other causes of childhood dystonia. OUP Academic

16. Pharmacologic responsiveness tracking. Systematic recording of function before and after levodopa over weeks documents sustained benefit and helps dose-titrate safely. NCBI

D) Electrodiagnostic tests

17. EEG (when encephalopathy is suspected). Often normal in classic DRD, but used if spells or developmental regression suggest seizures or encephalopathy in severe forms. PubMed

18. EMG during dystonia. May show co-contraction patterns but is mainly used to rule out peripheral nerve or muscle disorders when the picture is unclear. OUP Academic

E) Imaging tests

19. Brain MRI. Usually normal in classic DRD, which helps separate it from structural brain diseases; MRI is still important to exclude other causes of dystonia. OUP Academic

20. Dopamine terminal imaging (e.g., DAT-SPECT) in selected cases. In DRD, presynaptic terminals are often preserved, so DAT scans may be normal—another clue separating DRD from degenerative parkinsonism. This is not required for diagnosis but can help in difficult cases. OUP Academic

Non-pharmacological treatments (therapies & others)

Note: These do not replace levodopa if needed. They add function, reduce pain, and prevent falls. Evidence is strongest when therapy is combined with optimal medical care.

1. Physiotherapy (PT) for dystonia: regular PT trains posture, range, antagonist strengthening, and gait. It reduces pain and disability, especially combined with targeted medical care. Programs include stretching, task-specific practice, cueing, and relaxation drills. PMC+1

2. Task-specific motor retraining: repeated practice of the exact skill that is hard (walking, writing) builds new movement patterns and reduces overflow. PMC

3. Balance and fall-prevention training: static/dynamic balance work, step training, and home hazard checks cut fall risk. PMC

4. Stretching & positioning: daily, gentle, long-hold stretching with splints or orthoses limits contractures and eases pain. PMC

5. Strength training (antagonists): selective strengthening of muscles that oppose dystonic pulls can align joints and reduce abnormal postures. Movement Disorders Society

6. Cueing strategies: rhythmic counting, metronome steps, and visual lines can improve step initiation and speed in bradykinesia. Movement Disorders Society

7. Constraint or shaping techniques (task-specific): brief, guided constraint of the less-affected pattern to train the target task more cleanly. PMC

8. Biofeedback (EMG/visual): real-time feedback helps patients relax overactive muscles and recruit underused ones. Frontiers Publishing Partnerships

9. TENS or vibratory input: sensory tricks can dampen dystonic overflow and improve control for short periods in therapy. Frontiers Publishing Partnerships

10. Kinesiotaping/orthoses: taping and ankle-foot orthoses can guide joints, reduce pain, and support safer gait while retraining. Frontiers Publishing Partnerships

11. Occupational therapy (OT): adapts tools, writing aids, seating, and daily-living tasks; teaches energy conservation and joint protection. PMC

12. Speech-language therapy: helps voice control, breath support, and swallowing if bulbar symptoms are present. PMC

13. School accommodations: extra time, keyboard use, rest breaks, and safe PE plans maintain learning and participation. Massachusetts General Hospital

14. Psychological support/CBT: coping skills reduce stress-related worsening and help with chronic pain or anxiety. Frontiers Publishing Partnerships

15. Sleep hygiene: regular sleep supports daytime function; diurnal patterns often improve after rest. Movement Disorders

16. Pain self-management: heat/ice, gentle massage, pacing, and relaxation breathing lower muscle pain. BioMed Central

17. Aerobic exercise: safe, regular cardio improves endurance and mood; start low, go slow with guidance. Movement Disorders Society

18. Nutrition basics: steady meals, adequate protein spaced through the day; some centers use protein redistribution in levodopa-treated patients when meal competition with medication is suspected. (Specialist-directed.) PubMed

19. Assistive devices: canes or walkers as needed to prevent falls while therapy builds strength and control. Movement Disorders Society

20. Caregiver training: safe transfers, exercise carryover at home, and medication timing awareness improve outcomes. Massachusetts General Hospital

---

Drug treatments

Important: The drugs below are FDA-approved for Parkinson’s disease or related uses, not specifically for TH-DRD; in practice, clinicians often use them off-label to replace or support dopamine. Dosing must be individualized by a specialist. Citations below point to accessdata.fda.gov labels and key clinical literature.

Core dopamine replacement

1. Carbidopa/Levodopa (Sinemet) – Class: dopamine precursor + peripheral decarboxylase inhibitor. Dose/Time: individualized; carbidopa often ≥70–100 mg/day total to block nausea; divided doses. Purpose: main replacement for low dopamine. Mechanism: levodopa crosses BBB → dopamine; carbidopa blocks peripheral conversion. Side effects: nausea, orthostasis, dyskinesia with higher doses. FDA Access Data

2. Carbidopa/Levodopa CR (Sinemet CR) – Class: sustained-release form. Use: smoother levels, fewer doses. Cautions: variable absorption. Side effects: similar to IR. FDA Access Data

3. Carbidopa/Levodopa (Dhivy – scored) – Class: precise tablet scoring helps micro-titration in sensitive patients. Use: same as above with finer dose control. Side effects: as above. FDA Access Data

4. Carbidopa/Levodopa (Crexont – extended-release capsules) – Adults-labeled PD: newer ER profile; sometimes referenced for smoother kinetics. Mechanism/SE: as above. (Pediatric off-label decisions are specialist-led.) FDA Access Data+1

5. Carbidopa/Levodopa intestinal gel (Duopa) – Class: continuous jejunal infusion for advanced motor fluctuations. Use in TH-DRD: rarely needed; considered if severe fluctuations. Risks: device/PEG-J complications. FDA Access Data+1

Dopamine agonists (adjuncts when levodopa alone is not enough or to smooth response)

6. Pramipexole (Mirapex / Mirapex ER) – Class: D2/D3 agonist. Dose: titrated; adjust in renal impairment. Purpose: support dopamine signaling. Side effects: nausea, sleepiness, impulse-control disorders, edema. FDA Access Data+2FDA Access Data+2

7. Ropinirole (Requip / Requip XL) – Class: D2/D3 agonist. Use: similar to pramipexole. Side effects: nausea, dizziness, dyskinesia, sleep attacks; caution about hypotension. FDA Access Data+1

8. Rotigotine transdermal patch (Neupro) – Class: dopamine agonist patch for continuous delivery. Use: can help if swallowing is hard; apply daily to skin. Side effects: application-site reactions, nausea, somnolence. FDA Access Data

MAO-B inhibitors (reduce dopamine breakdown; may allow lower levodopa dose)

9. Selegiline (Eldepryl / Zelepar ODT / EMSAM for depression) – Class: MAO-B inhibitor (oral selegiline for PD). Dose: low, morning dosing. Side effects: insomnia, interactions with serotonergic drugs; EMSAM is for depression, not PD. FDA Access Data+2FDA Access Data+2

10. Rasagiline (Azilect / generic) – Class: MAO-B inhibitor. Use: once daily adjunct; helps “wearing-off.” Side effects: headache, arthralgia; interaction cautions. FDA Access Data+1

11. Safinamide (Xadago) – Class: MAO-B inhibitor with glutamate-modulating actions. Use: adjunct for “OFF” time. Side effects: dyskinesia, insomnia; avoid in severe hepatic impairment. FDA Access Data+1

COMT inhibitors (prolong levodopa effect)

12. Entacapone (Comtan) – Class: COMT inhibitor taken with each levodopa dose. Purpose: extends levodopa action. Side effects: diarrhea, orange urine, dyskinesia. FDA Access Data

13. Opicapone (Ongentys) – Class: once-daily COMT inhibitor. Use: reduces OFF time in PD; may simplify dosing. Cautions: hepatic impairment dose limits. Side effects: insomnia, dyskinesia. FDA Access Data+1

14. Tolcapone (Tasmar) – Class: COMT inhibitor. Note: carries serious liver toxicity risk; restricted use and monitoring required. Side effects: diarrhea, orthostasis, hepatotoxicity. FDA Access Data+2FDA Access Data+2

Other dopaminergic/adjunct agents

15. Amantadine (Gocovri ER / amantadine IR) – Class: NMDA antagonist with dopaminergic effects; used mainly for dyskinesia or tremor. Side effects: hallucinations, livedo reticularis, ankle edema. FDA Access Data+1

Clinical experience in TH-DRD: The cornerstone is low-to-moderate levodopa started carefully; early treatment can improve developmental outcomes, but dyskinesia can appear early if doses are raised too fast—so titration must be slow and supervised. Movement Disorders+1

---

Dietary molecular supplements

There is no supplement proven to cure TH-DRD. Basic nutrition supports general health; any supplement should be clinician-guided.

1. Balanced protein with specialist-directed “protein redistribution” when levodopa interactions are suspected (protein competes with levodopa transport). Rarely used in kids; only with expert dietitian oversight. PubMed

2. Iron (if deficient): TH uses iron as a cofactor; correct frank deficiency per guidelines. Do not self-dose high iron without labs. PMC

3. Vitamin C with meals: may help iron absorption when iron is prescribed. Evidence is general hematology, not TH-specific. PMC

4. General multivitamin/mineral: covers dietary gaps; no disease-specific benefit proven. PMC

5. Omega-3 fatty acids: broad neuro-support signal; no TH-specific data, but safe dietary inclusion is reasonable. PMC

6. Adequate hydration and fiber: supports gut motility when on dopaminergic drugs that may cause constipation. FDA Access Data

7. Tyrosine: TH is rate-limiting; extra tyrosine does not bypass the block. No human TH-DRD evidence for benefit; animal BH4-defect models are not directly applicable. PLOS

8. BH4 (tetrahydrobiopterin): TH requires BH4, but in pure TH-DRD BH4 levels are usually normal; BH4 therapy is not standard. Discuss only in research settings. PMC

9. Vitamin B12/folate (if low): correct deficiencies that can mimic/worsen neuropathic symptoms. PMC

10. Avoid unproven “dopamine boosters” sold online; no evidence in TH-DRD and potential interactions with MAO-B inhibitors. FDA Access Data

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity boosters,” regenerative medicines, or stem-cell drugs for TH-DRD. No approved gene therapy exists for TH-DRD as of October 7, 2025. Care focuses on dopamine replacement (levodopa), selected adjuncts, and rehabilitation. If you see claims online, treat them as experimental and discuss risks in a research ethics framework. PMC

---

Surgeries

Surgery is not routine for TH-DRD because medicine usually works very well. In rare, severe, or levodopa-resistant cases, specialists may consider:

1. Deep brain stimulation (DBS), GPi target – case series and reports show benefit in some levodopa-resistant DRD. Decision is highly individualized. PubMed+1

2. DBS, STN target – isolated pediatric cases reported when symptoms were severe and drug-refractory. PubMed

3. Intrathecal baclofen pump – mainly for spasticity; very selective use if mixed tone disorder persists despite optimal dopamine therapy. (Evidence in DRD is sparse.) PMC

4. Orthopedic soft-tissue procedures – for fixed contractures after long-standing dystonia; goal is comfort and alignment, not disease cure. PMC

5. PEG-J for Duopa – a device procedure rather than neurosurgery; used only when continuous levodopa is clearly needed and benefits outweigh risks. FDA Access Data

---

Preventions

1. Early specialist care if gait or posture problems start. Early levodopa improves outcomes. Movement Disorders

2. Avoid dopamine-blocking drugs (certain antipsychotics, metoclopramide) unless essential and supervised. FDA Access Data

3. Vaccinations & infection control to prevent deconditioning from illness. PMC

4. Sleep regularity to limit diurnal worsening. Movement Disorders

5. Safe home setup (rails, remove trip hazards) to cut falls. BioMed Central

6. Physio “pre-habilitation” (stretching/strength) to keep range and alignment. PMC

7. Nutrition basics and medication timing awareness (protein and levodopa interactions). PubMed

8. Monitor for dyskinesia when increasing levodopa; report early movements. PubMed

9. Family genetic counseling for future pregnancies (autosomal recessive). PMC

10. Regular follow-ups to adjust doses as the child grows or needs change. Wiley Online Library

---

When to see a doctor (red flags)

Seek care if: symptoms start in childhood, gait becomes unsafe, new falls occur, there is sudden worsening after a new medicine, swallowing or feeding becomes hard, there are uncontrolled involuntary movements after a dose change, or there is regression in development. These signs need prompt specialist review and medication adjustment. Wiley Online Library+1

---

What to eat and what to avoid

Eat regular, balanced meals with vegetables, fruits, whole grains, lean proteins, and healthy fats. If you take levodopa, ask your team whether protein timing matters for you; some centers move more protein to evening to reduce daytime competition with levodopa transport. Stay hydrated and keep fiber up to prevent constipation from dopaminergic drugs. Avoid fad “dopamine booster” supplements and large, sudden protein loads right with levodopa doses unless your clinician says it is fine. PubMed+1

---

FAQs

1) Is TH-DRD curable?
No permanent cure exists, but many people do very well on levodopa plus therapy. Early treatment improves function. Movement Disorders

2) How is TH-DRD proven?
A mix of history, exam, CSF neurotransmitters (low HVA, often normal 5-HIAA), and TH gene testing. PMC

3) Does everyone respond to levodopa?
Most do well, but the dose window can be narrow; dyskinesias can occur if titrated too fast. PubMed

4) Is BH4 a treatment here?
Usually no in pure TH-DRD because BH4 levels are typically normal; BH4 therapy is not standard. Pedneur

5) Are dopamine agonists needed?
Sometimes, as add-ons when levodopa alone does not smooth symptoms. Off-label in TH-DRD; watch side effects. FDA Access Data+1

6) What about COMT or MAO-B inhibitors?
They can prolong dopamine action or reduce breakdown; used individually with careful monitoring. FDA Access Data+1

7) Is DBS a common solution?
No. DBS is a last-line option for rare, drug-refractory cases; small reports show it can help selected patients. PubMed+1

8) Can diet fix TH-DRD?
Diet supports health, but it does not replace levodopa. Some centers adjust protein timing in levodopa users. PubMed

9) Are there warning drugs to avoid?
Avoid dopamine-blocking agents unless essential (e.g., certain antipsychotics, metoclopramide). FDA Access Data

10) Can children outgrow it?
No; it is genetic. But early, steady treatment can normalize or greatly improve movement and development. American Academy of Neurology

11) Are stem cells or gene therapy available?
No approved options for TH-DRD as of October 7, 2025. Research is ongoing. MDPI

12) Why do symptoms vary by day?
Dopamine tone varies with sleep and activity; many have evening worsening (diurnal fluctuation). Movement Disorders

13) What tests track progress?
BFMDRS-M, gait speed, pain scales, quality-of-life tools, and pre/post video. Frontiers+1

14) What if levodopa causes new movements?
Tell your clinician. Doses may need to be reduced and titrated more slowly; dyskinesia is reported in TH-DRD when escalated too fast. PubMed

15) Where can I read a trusted overview?
GeneReviews is an excellent clinician-level summary; patient guides from major hospitals are also helpful. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 06, 2025.